Literature DB >> 30778612

[Modern HIV treatment].

C Lehmann1,2, J Malin3, I Suárez4,3, G Fätkenheuer4,3.   

Abstract

Human immunodeficiency virus (HIV) infection has become a chronic disease with a favourable prognosis if adequate antiretroviral therapy (ART) is applied. Therefore, each patient with HIV infection should be treated irrespectively of clinical symptoms or of immunological status. A combination of three active drugs that have to be taken life-long has been standard for many years. The regimen contains two nucleoside reverse transcriptase inhibitors plus either an integrase inhibitor, a boosted protease inhibitor, or a non-nucleoside reverse transcriptase inhibitor. Integrase inhibitors are recommended as the third partner of choice by recent guidelines due to their high efficacy and their favourable safety profile. Many combination drugs are now available which allow a simple treatment with few tablets and in many instances a one-pill combination per day is an option. Potential interactions with drugs given for other diseases have to be taken into account, especially if a pharmacological booster is part of the regimen. Combination therapy should be changed if either virological failure (HIV RNA >200 copies/ml) or drug-related adverse events occur. In special situations (e. g. pregnancy) highly experienced experts in the field should be consulted. Novel approaches for HIV therapy include dual therapy as well as treatment with long-acting substances. Beside therapy, antiretroviral drugs are used for prevention either as post-exposure prophylaxis or as pre-exposure prophylaxis.

Entities:  

Keywords:  Anti-retroviral agents; Integrase inhibitors; Post-exposure prophylaxis; Pre-exposure prophylaxis; Reverse transcriptase inhibitors

Mesh:

Substances:

Year:  2019        PMID: 30778612     DOI: 10.1007/s00108-019-0564-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  19 in total

Review 1.  Novel therapies based on mechanisms of HIV-1 cell entry.

Authors:  J Michael Kilby; Joseph J Eron
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

2.  HIV transmission despite HIV post-exposure prophylaxis after non-occupational exposure.

Authors:  Christiane Cordes; Arend Moll; Claudia Kuecherer; Ulrich Marcus
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

3.  Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

Authors:  Josep M Llibre; Chien-Ching Hung; Cynthia Brinson; Francesco Castelli; Pierre-Marie Girard; Lesley P Kahl; Elizabeth A Blair; Kostas Angelis; Brian Wynne; Kati Vandermeulen; Mark Underwood; Kim Smith; Martin Gartland; Michael Aboud
Journal:  Lancet       Date:  2018-01-06       Impact factor: 79.321

4.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Authors:  Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden
Journal:  Lancet Infect Dis       Date:  2014-07-22       Impact factor: 25.071

5.  Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Authors:  Pedro Cahn; Juan Sierra Madero; José Ramón Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Man; Alexander Currie; Mark Underwood; Allan R Tenorio; Keith Pappa; Brian Wynne; Anna Fettiplace; Martin Gartland; Michael Aboud; Kimberly Smith
Journal:  Lancet       Date:  2018-11-09       Impact factor: 79.321

6.  Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Authors:  Eric S Daar; Edwin DeJesus; Peter Ruane; Gordon Crofoot; Godson Oguchi; Catherine Creticos; Jürgen K Rockstroh; Jean-Michel Molina; Ellen Koenig; Ya-Pei Liu; Joseph Custodio; Kristen Andreatta; Hiba Graham; Andrew Cheng; Hal Martin; Erin Quirk
Journal:  Lancet HIV       Date:  2018-06-18       Impact factor: 12.767

7.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Authors:  Jean-Michel Molina; Isabelle Charreau; Bruno Spire; Laurent Cotte; Julie Chas; Catherine Capitant; Cecile Tremblay; Daniela Rojas-Castro; Eric Cua; Armelle Pasquet; Camille Bernaud; Claire Pintado; Constance Delaugerre; Luis Sagaon-Teyssier; Soizic Le Mestre; Christian Chidiac; Gilles Pialoux; Diane Ponscarme; Julien Fonsart; David Thompson; Mark A Wainberg; Veronique Doré; Laurence Meyer
Journal:  Lancet HIV       Date:  2017-07-23       Impact factor: 12.767

8.  Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.

Authors:  Wan-Lin Yang; Roger Kouyos; Alexandra U Scherrer; Jürg Böni; Cyril Shah; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Hansjakob Furrer; Manuel Battegay; Matthias Cavassini; Enos Bernasconi; Pietro Vernazza; Leonhard Held; Bruno Ledergerber; Huldrych F Günthard
Journal:  J Infect Dis       Date:  2015-01-09       Impact factor: 5.226

9.  Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Authors:  Joel Gallant; Adriano Lazzarin; Anthony Mills; Chloe Orkin; Daniel Podzamczer; Pablo Tebas; Pierre-Marie Girard; Indira Brar; Eric S Daar; David Wohl; Jürgen Rockstroh; Xuelian Wei; Joseph Custodio; Kirsten White; Hal Martin; Andrew Cheng; Erin Quirk
Journal:  Lancet       Date:  2017-08-31       Impact factor: 79.321

10.  Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.

Authors:  Chloe Orkin; Kathleen E Squires; Jean-Michel Molina; Paul E Sax; Wing-Wai Wong; Otto Sussmann; Richard Kaplan; Lisa Lupinacci; Anthony Rodgers; Xia Xu; Gina Lin; Sushma Kumar; Peter Sklar; Bach-Yen Nguyen; George J Hanna; Carey Hwang; Elizabeth A Martin
Journal:  Clin Infect Dis       Date:  2019-02-01       Impact factor: 9.079

View more
  2 in total

Review 1.  Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals.

Authors:  Angélica Saraí Jiménez-Osorio; Sinaí Jaen-Vega; Eduardo Fernández-Martínez; María Araceli Ortíz-Rodríguez; María Fernanda Martínez-Salazar; Reyna Cristina Jiménez-Sánchez; Olga Rocío Flores-Chávez; Esther Ramírez-Moreno; José Arias-Rico; Felipe Arteaga-García; Diego Estrada-Luna
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

2.  Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients in Southeast China.

Authors:  Jinglan Lai; Yuming Liu; Xiao Han; Aiqiong Huang; Jin Lin; Wen Ao; Hanhui Ye; Yahong Chen
Journal:  Drug Des Devel Ther       Date:  2021-02-26       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.